Note: Descriptions are shown in the official language in which they were submitted.
CA 03067963 2019-12-19
TREATMENT AGENT FOR EPIDERMOLYSIS BULLOSA
TECHNICAL FIELD
[0001]
The present invention relates to a cell product in regenerative therapy.
More particularly, the present invention relates to a cell product comprising
a
pluripotent stem cell, the cell product being effective for treatment of
epidermolysis bullosa, and to a cell product comprising a skin cell
differentiated
from a pluripotent stem cell, the cell product being effective for treatment
of
skin diseases such as epidermolysis bullosa.
BACKGROUND ART
[0002]
Epidermolysis bullosa (EB) is a serious hereditary bullous skin disease in
which genetic abnormalities in adhesion structure control proteins in a skin
basement membrane zone disrupt the adhesion functions between epidermis and
dermis, allowing epidermis to peel off at the basement membrane level with a
slight external force in daily life and forming blisters and/or ulcers (Table
1).
Depending on the site where blisters form, epidermolysis bullosa is divided
into
three main types: epidermolysis bullosa simplex, junctional epidermolysis
bullosa, and dystrophic epidermolysis bullosa. Epidermolysis bullosa causes
blisters and/or erosions with slight external forces at sites that are
susceptible to
external forces, such as peripheral extremities and large joints. Blisters and
erosions associated with epidermolysis bullosa simplex and dominant
epidermolysis bullosa dystrophica are relatively rapidly healed. After being
1
CA 03067963 2019-12-19
healed, they do not leave scars or skin atrophy in epidermolysis bullosa
simplex
but leave scars in dominant epidermolysis bullosa dystrophica. On the other
hand, blisters and erosions associated with junctional epidermolysis bullosa
and
recessive epidermolysis bullosa dystrophica are intractable in general. When
healed, they leave skin atrophy in junctional epidermolysis bullosa while
leaving
scars in recessive epidermolysis bullosa dystrophica. Epidermolysis bullosa is
difficult to identify from clinical findings at birth, and thus comprehensive
diagnosis is made in combination with electron microscope, immunostaining,
genetic diagnosis, and clinical findings changing with growth. Early diagnosis
provides effective information to successfully manage skin and whole body.
Diagnosis and treatment of rare intractable diseases require special
facilities as
well as examination by and advice from medical specialist.
Table 1
<Disease types, Responsible Genes and Proteins>
Type Main Subtype Responsible Genes and Proteins
Weber-Cockayne
Epidermolysis Koebner Keratin 5, Keratin 14
Bullosa Dowling-Meara
Simplex
with muscular dystrophy Plectin
with pyloric atresia Plectin
Junctional Herlitz LAMA3, LAMM, LAMC2(Laminin 332)
Epidermolysis LAMM, LAMB3,1..AMC2(Laminin 332)
Bullosa non-Herlitz
Collagen type XVII
with pyloric atresia fTGA6, rrGB4( a 6134 Integrin )
Dominant
Dystrophic
Epidermolysis Severe generalized recessive Collagen type VII
Bullosa
Recessive, other generalized
Cited from homepage for research groups on rare intractable skin diseases
"epidermolysis bullosa"
2
CA 03067963 2019-12-19
[0003]
Methods for treating epidermolysis bullosa are symptomatic treatments
only, and radical treatment does not exist currently. Since the symptomatic
treatments also depend on the type of the disease, accurate diagnosis of type
is
first essential. In addition, epidermolysis bullosa may develop various
complications depending on the type and worsen the condition, significantly
restricting daily living of the patient, and thus treatments for the various
complication are also needed. Furthermore, since epidermolysis bullosa is an
intractable hereditary disease, it is also necessary to consider prevention of
recurrence in patients in the family.
[0004]
<Local Treatment>
A blister, erosion, or ulcer is washed with water, and then a petrolatum
gauze or the like is applied thereon to prevent adhesion between the gauze and
the erosion. At this time, the blister is pre-punctured to remove the content
(without removing the blister lid). In cases involving adhesion between
fingers,
a petrolatum gauze or the like is put between the fingers to prevent adhesion
between fingers. Because prolonged use of ointments containing antibiotics can
cause the emergence of resistant bacteria, ointments containing antibiotics
are
not positively and necessarily used except in special cases. If erosion or
ulcer
worsens, there can be risk of complicated fungal or bacterial infections, and
skin
carcinoma particularly in recessive dystrophic epidermolysis bullosa. For this
reason, skin biopsy, fungal test, bacterial culture test, and the like are
positively
performed. In general, ointment treatment is applied once a day.
[0005]
<Systemic Treatment>
3
. )
CA 03067963 2019-12-19
. .
i .
Nutrition Supplementation: Especially in cases of recessive dystrophic
epidermolysis bullosa, due to oral mucosal and esophageal lesions, nutrient
intake is insufficient, and thus chronic malnutrition and anemia are very
common. Therefore, oral intake of nutrients such as ENSURE LIQUID is useful.
If oral intake is difficult, nutrients may be supplemented with a nasal tube
or
infusion. Anti-histamines may be effectively used for severe itching.
[0006]
<Treatment for Complications>
In cases of recessive epidermolysis bullosa dystrophica and junctional
epidermolysis bullosa, for example, adhesion between fingers, malignant skin
tumor, esophageal stenosis, pyloric stenosis, anal erosion and stenosis,
malnutrition, conjunctival erosion, anemia are often problematic. In addition,
one of serious complications is secondary systemic amyloidosis.
Many of the complications of epidermolysis bullosa significantly reduce
the quality of life, and therefore the demand for therapy is high. It is
important
to provide diagnosis and treatment with the cooperation of specialists in
various
clinical fields, such as plastic surgery, dilation, and nutrition management
(Non-
Patent Document 1).
[0007]
However, since a safe and reliable methodology for normalizing genetic
abnormalities has not yet been established, there is no radical treatment for
hereditary diseases such as epidermolysis bullosa at present.
On the other hand, with the recent progress in research on regenerative
therapy, treatments of epidermolysis bullosa by bone marrow transplantation,
bone marrow stem cell transplantation and the like have been searched.
[0008]
4
A t
CA 03067963 2019-12-19
. .
. A
For example, findings as described below have been reported (Non-Patent
Document 2).
(1) Mechanism of Skin Regeneration by Bone Marrow-derived Cells: As
a mechanism of epidermal regeneration in skin of a patient with epidermolysis
bullosa, where large amounts of epidermal stem cells have been lost after many
years of extensive epidermal detachment, stem cells in the bone marrow are
found to be recruited to the injured skin through the peripheral circulation
and
contribute to the regeneration of the skin with blisters (Non-Patent Documents
3
and 4).
(2) Bone Marrow Transplantation Therapy for Epidermolysis Bullosa: A
research group at the University of Minnesota, USA, performed for the first
time
in the world bone marrow transplantation for recessive dystrophic
epidermolysis
bullosa, and reported the effect of improving the skin symptoms. However, in 2
of 7 cases patients died during the course, and thus development of a safer
protocol for bone marrow transplantation therapy is essential (Non-Patent
Document 5).
(3) Bone Marrow Mesenchymal Stem Cell Transplantation Therapy for
Epidermolysis Bullosa: A study group in Chile, South America, subcutaneously
transplanted bone marrow-derived cultured mesenchymal stem cells from a
healthy subject to two cases of severe recessive dystrophic epidermolysis
bullosa, and determined the effectiveness (Non-Patent Document 6). In
addition,
UK and Egyptian groups administered via infusion marrow-derived cultured
mesenchymal stem cells from a healthy subject to patients with severe
recessive
dystrophic epidermolysis bullosa, and reported the effectiveness (Non-Patent
Documents 7 and 8). However, it was also found that the transplanted
mesenchymal stem cells can gradually decrease in a few months.
= I
CA 03067963 2019-12-19
. .
= =
(4) Feasibility of Regeneration-inducing Therapy for Epidermolysis
Bullosa Using a Factor for Recruiting Bone Marrow Mesenchymal Stem Cell in
Blood: HMGB1 released from detached epidermis was found to cause bone
marrow mesenchymal stem cells to accumulate in detached epidermal skin via
peripheral blood and strongly induce regeneration of the damaged skin (Non-
Patent Document 4).
As described above, intensive basic and clinical researches on gene
therapy and regenerative therapy are progressed with the aim of developing
radical therapy for epidermolysis bullosa. However, safe and effective therapy
that completely cures epidermolysis bullosa has not yet been found, and
therefore further radical therapies are demanded to be realized.
[0009]
Studies by Izawa et al. have revealed that pluripotent stem cells that are
present in mesenchymal cell fractions, can be obtained without gene
introduction
or induction by cytokines or the like, and express SSEA-3 (Stage-Specific
Embryonic Antigen-3) as a surface antigen (Multilineage-differentiating Stress
Enduring cells; Muse cell) can be responsible for the pluripotency possessed
by
the mesenchymal cell fractions, and applied to disease treatment aimed at
tissue
regeneration (e.g., Patent Document 1; Non-Patent Documents 9 to 11).
However, it has not been demonstrated whether use of Muse cells in treatment
of
epidermolysis bullosa could provide expected therapeutic effects.
PRIOR ART DOCUMENTS
PATENT DOCUMENTS
[0010]
Patent Document 1: Japanese Patent No. 5185443
6
1 .
CA 03067963 2019-12-19
. .
r
NON-PATENT DOCUMENTS
[0011]
Non-patent Document 1: Homepage for research groups on rare
intractable skin diseases (http://kinan.info/)
Non-patent Document 2: Tamai K. J Natl Inst Public Health 2011; 60:
118-124.
Non-patent Document 3: Chino T et al. Am J Pathol 2008; 173: 803-814.
Non-patent Document 4: Tamai K et al. Proc Natl Acad Sci USA 2011;
108: 6609-6614.
Non-patent Document 5: Wagner JE et al. N Engl J Med 2010; 363: 629-
639.
Non-patent Document 6: Conget P et al. Cytotherapy 2010; 12: 429-431.
Non-patent Document 7: Petrof G et al. J Invest Dermatol 2015; 135:
2319-2321.
Non-patent Document 8: El-Darouti M et al. Dermatol Ther 2016; 29: 96-
100.
Non-patent Document 9: Kuroda Y et al. Proc Natl Acad Sci USA 2010;
107: 8639-8643.
Non-patent Document 10: Wakao S et al. Proc Natl Acad Sci USA 2011;
108: 9875-9880.
Non-patent Document 11: Kuroda Yet al. Nat Protc 2013; 8: 1391-1415.
SUMMARY OF THE INVENTION
[0012]
An object of the present invention is to provide a cell product for
treatment of skin diseases such as epidermolysis bullosa.
7
CA 03067963 2019-12-19
=
[0013]
The present inventors found that administration of human Muse cells to a
mouse having experimentally injured skin via its blood vessel leads to
expression
of human collagen at the wound site, which facilitates wound repair. The
present
inventors also found that after blister formation in the epidermis of a
collagen
type XVII (COL17) gene-deficient mouse model of epidermolysis bullosa,
administration of human Muse cells via its blood vessel or the like can
provide
human collagen type XVII to the epidermis, meaning that Muse cells can be used
in treatment of epidermolysis bullosa. The present inventors further found
that
skin cells that are effective in treatment of skin diseases, such as
keratinocytes
and fibroblasts, can be obtained from Muse cells, thereby completed the
present
invention.
[0014]
Accordingly, the present invention provides the following [1] to [11]:
[1] A cell product for treatment of epidermolysis bullosa, comprising a
SSEA-3-positive pluripotent stem cell derived from a mesenchymal tissue in a
living body or a cultured mesenchymal cell;
[2] The cell product of item [1], wherein said epidermolysis bullosa is
epidermolysis bullosa simplex;
[3] The cell product of item [1], wherein said epidermolysis bullosa is
junctional epidermolysis bullosa;
[4] The cell product of item [1], wherein said epidermolysis bullosa is
dystrophic epidermolysis bullosa;
[5] The cell product of item [4], wherein said dystrophic epidermolysis
bullosa is dominant dystrophic epidermolysis bullosa or recessive dystrophic
epidermolysis bullosa;
8
= =
CA 03067963 2019-12-19
, .
=
[6] The cell product of any one of items [1] to [5], wherein said
pluripotent
stem cell is one having all of the following characteristics:
(i) having low or no telomerase activity;
(ii) capable of differentiating into any of tridermic cells;
(iii) showing no neoplastic proliferation; and
(iv) having self-renewal capacities;
[7] The cell product of any one of items [1] to [5], wherein said
pluripotent
stem cell is one having all of the following characteristics:
(i) SSEA-3 positive;
(ii) CD105 positive;
(iii) having low or no telomerase activity;
(iv) capable of differentiating into any of tridermic cells;
(v) showing no neoplastic proliferation; and
(vi) having self-renewal capacities;
[8] A skin cell differentiated from a SSEA-3-positive
pluripotent stem cell
derived from a mesenchymal tissue in a living body or a cultured mesenchymal
cell;
[9] The skin cell of item [8], wherein said skin cell is a
keratinocyte and/or a
fibroblast;
[10] A cell product for treatment of a skin disease, comprising
the skin cell of
item [8] or [9];
[11] The cell product of item [10], wherein said skin disease is
epidermolysis
bullosa;
[12] A method for treating epidermolysis bullosa, comprising a
step of
administering an effective dose of the cell product of any one of items [1] to
[6]
to a patient in need thereof.
9
1 s
CA 03067963 2019-12-19
. .
[0015]
According to the present invention, Muse cells can be administered to a
patient with epidermolysis bullosa via a blood vessel or the like, or directly
to its
skin site forming a blister or erosion and its periphery, to reconstruct and
repair
the damaged skin, thereby ameliorating or healing the skin symptoms. Thus, the
cell product comprising Muse cells of the present invention can be used for
treatment of epidermolysis bullosa.
[0016]
Since Muse cells can efficiently migrate and engraft to a skin site
forming a blister or erosion, and then spontaneously differentiate into
epidermal
cells at the engraftment site, they do not require differentiation induction
into
cells to be treated prior to transplantation. In addition, Muse cells are non-
tumorigenic and excellent in safety. Furthermore, since Muse cells does not
induce any immune rejection, treatment with alIogenic preparations produced
from donors is also possible. Therefore, Muse cells having the excellent
characteristics as described above can provide easy and viable means for
treatment of patients with epidermolysis bullosa.
[0017]
According to the present invention, skin cells differentiated from Muse
cells, such as keratinocytes or fibroblasts, can be administered to a site
affected
by a skin disease and its periphery of a patient with the skin disease such as
epidermolysis bullosa to reconstruct and repair the damaged skin, thereby
ameliorating or healing the skin symptoms. Thus, the cell product comprising
skin cells differentiated from Muse cells of the present invention can be used
for
treatment of skin diseases such as epidermolysis bullosa.
. .
CA 03067963 2019-12-19
. .
BRIEF DESCRIPTION OF THE DRAWINGS
[0018]
FIG. 1 shows photographs of wound sites of full-thickness wound model
mice in each group (day 0, 3, 6, or 9 after administration).
FIG. 2 is a graph showing changes over time in the epithelization rate in
wound sites of full-thickness wound model mice in each group.
FIG. 3, the photomicrographs shows the results of staining of human
nuclei and human collagen type VII (COL7) in tissue sections of wound sites of
full-thickness wound model mice in each group.
FIG. 4 shows the skin state of a COL17-knockout mouse after
administration of Muse cells (middle) or HBSS (right). The left shows a mouse
before administration.
FIG. 5 shows the results of electrophoresis for RT-PCR analysis for the
expressions of human COL7 gene (A) and human COL17 gene (B) in a skin of a
COL17-knockout mouse administered with Muse cells. Lane L corresponds to a
marker for electrophoresis; and lanes 1 to 6 show the results for six COL17-
knockout mice administered with Muse cells; lane 7 for a normal human
keratinocyte (positive control); lane 8 for a normal B6 mouse (negative
control);
and lane 9 for water only.
FIG. 6 depicts photomicrographs showing the results of human COL7
staining in skin tissue sections from a COL17-knockout mouse administered with
Muse cells.
FIG. 7 shows Muse cells differentiating into keratinocytes.
FIG. 8 shows the results of immunostaining for expression of
keratinocyte markers in a keratinocyte differentiated from a Muse cell.
FIG. 9 shows the results of RT-PCR for expression of keratinocyte
11
r =
CA 03067963 2019-12-19
. ,
r
markers in a keratinocyte differentiated from a Muse cell.
FIG. 10 shows Muse cells differentiating into fibroblasts.
FIG. 11 shows the results of immunostaining for expression of fibroblast
markers in a fibroblast differentiated from a Muse cell.
FIG. 12 shows the results of RT-PCR for expression of fibroblast markers
in a fibroblast differentiated from a Muse cell.
DETAILED DESCRIPTION OF THE INVENTION
[0019]
<1> Cell product Comprising Muse Cell
The present invention relates to a cell product for treatment of
epidermolysis bullosa, the cell product comprising a SSEA-3-positive
pluripotent
stem cell (Muse cell). The treatment includes healing, ameliorating, and
preventing relapse of the symptoms. The present invention will be described in
detail below.
[0020]
1. Indications
The cell product comprising a SSEA-3-positive pluripotent stem cell
(Muse cell) of the present invention is used for treatment of epidermolysis
bullosa.
As used herein, the term "epidermolysis bullosa" refers to a serious
hereditary bullous skin disease where genetic abnormalities in adhesion
structure
control proteins in a skin basement membrane zone, for example, cause
disruption of the adhesion functions between the epidermis and dermis,
allowing
epidermis to peel off at the basement membrane level with a slight external
force
in daily life and forming a blister, ulcer and/or erosion.
12
a ,
CA 03067963 2019-12-19
. ,
[0021]
In the present invention, epidermolysis bullosa is divided, depending on
where blister form, into three main types: epidermolysis bullosa simplex,
junctional epidermolysis bullosa, and dystrophic epidermolysis bullosa (e.g.,
dominant dystrophic epidermolysis bullosa, and recessive dystrophic
epidermolysis bullosa). Epidermolysis bullosa causes a blister or erosion due
to
slight external forces at sites that are susceptible to external forces, such
as
peripheral extremities and large joints.
[0022]
2. Cell product
(1) Pluripotent Stem Cell (Muse Cell)
The pluripotent stem cell used in the cell product of the present invention
is a cell that was found in human living body and named "Muse (Multilineage-
differentiating Stress Enduring) cell" by Dezawa et al. It is known that Muse
cells can be obtained from, for example, bone marrow fluid, adipose tissues
(Ogura, F., et al., Stem Cells Dev., Nov 20, 2013 (Epub) (published on Jan 17,
2014)) and dermal connective tissues of skin, and are broadly present in
tissues
and connective tissues in organs. This cell also has both characteristics of
pluripotent stem cell and mesenchymal stem cell and is identified as, for
example, a cell positive for "SSEA-3 (Stage-specific embryonic antigen-3)," a
cell surface marker, preferably as a double-positive cell that is positive for
SSEA-3 and CD-105. Therefore, Muse cells or a cell population containing
Muse cells can be isolated from tissues in a living body using, for example,
expression of SSEA-3 only or a combination of SSEA-3 and CD-105 as an index.
Methods for separation and identification of, and characteristics of Muse cell
have been specifically disclosed in W02011/007900. Muse cells can also
13
CA 03067963 2019-12-19
selectively enriched by utilizing their high resistance to various external
stresses
and culturing them under various external stress conditions, such as under
protease treatment, under hypoxic condition, under low-phosphate condition, in
a
low serum concentration, under undernutrition condition, under heat shock
exposure, in the presence of toxic substance, in the presence of active
oxygen,
under mechanical stimulation, and under pressure treatment. As used herein,
the
pluripotent stem cells (Muse cells) or a cell population containing Muse cells
prepared, as a cell product for treating epidermolysis bullosa, from a
mesenchymal tissue in a living body or cultured mesenchymal tissues using
SSEA-3 as an index may be simply referred to as "SSEA-3-positive cells." As
used herein, the term "non-Muse cells" may refer to cells contained in a
mesenchymal tissue in a living body or cultured mesenchymal cells and
excluding "SSEA-3-positive cells."
[0023]
Muse cells or a cell population containing Muse cells can be prepared
from tissues (e.g., mesenchymal tissues) in a living body using cell surface
markers, SSEA-3, or SSEA-3 and CD-105, as an index(es). As used herein, the
term "living" body means mammal living body. In the present invention, the
living body does not include fertilized egg and embryos in developmental
stages
before blastula stage, but includes embryos in developmental stages of
blastula
stage or later, including fetus and blastula. Examples of the mammal include,
but not limited to, primates such as human and monkey; rodents such as mouse,
rat, rabbit, and guinea pig; and cat, dog, sheep, pig, cattle, horse, donkey,
goat,
and ferret. The Muse cell to be used in the cell product of the present
invention
is definitively distinguished from embryonic stem cells (ES cells) and induced
pluripotent stem (iPS) cells in that the Muse cell is directly isolated from a
tissue
14
=
CA 03067963 2019-12-19
=
in a living body with a marker. The term "mesenchymal tissue" refers to
tissues
such as bone, synovial membrane, fat, blood, bone marrow, skeletal muscle,
dermis, ligament, tendon, dental pulp, umbilical cord, cord blood, and amnion,
and tissues present in various organs. The Muse cells can be obtained from,
for
example, bone marrow, skin, adipose tissue, blood, dental pulp, umbilical
cord,
cord blood, and amnion. Preferably, a mesenchymal tissue in a living body is
collected, and then Muse cells are prepared from the tissue and used.
Alternatively, using the preparation method described above, the Muse cells
may
be prepared from cultured mesenchymal cells such as fibroblast and bone marrow
mesenchymal stem cell.
[0024]
The cell population containing Muse cells to be used in the cell product
of the present invention can also be prepared by a method comprising
stimulating
a mesenchymal tissue in a living body or cultured mesenchymal cells with an
external stress to selectively allow cells with the resistance to the external
stress
to grow and collecting the cells with an increased abundance ratio.
The external stress may be any one of or a combination of the followings:
protease treatment, culturing under low oxygen concentration, culturing under
low-phosphate condition, culturing under low serum concentration, culturing
undernutrition condition, culturing under heat shock exposure, culturing at
low
temperatures, freezing treatment, culturing in the presence of toxic
substances,
culturing in the presence of active oxygen, culturing under mechanical
stimulation, culturing under shaking, culturing under pressure treatment or
physical shocks.
The protease treatment is preferably carried out for 0.5 to 36 hours in
total to exert the external stress. The concentration of the protease may be
that
. .
CA 03067963 2019-12-19
. .
used when cells adhered to a culture vessel are peeled off, when cell
aggregates
are separated into single cells, or when single cells are collected from a
tissue.
Preferably, the protease is serine protease, aspartic protease, cysteine
protease, metalloprotease, glutamic protease or N-terminal threonine protease.
More preferably, the protease is trypsin, collagenase or Dispase.
[0025]
The Muse cell to be used in the cell product of the present invention may
be autologous or allogeneic to a recipient to be transplanted with the cell.
[0026]
As described above, Muse cells or a cell population containing Muse
cells can be prepared from tissues in a living body, for example, by using
SSEA-
3-positivity or SSEA-3 and CD-105-double-positivity as an index. Human adult
skin is known to comprise various types of stem cells and precursor cells.
However, Muse cell is different from these cells. These stem cells and
precursor
cells include skin-derived precursor cell (SKP), neural crest stem cell
(NCSC),
melanoblast (MB), pericyte (PC), endothelial precursor cell (EP), and adipose-
derived stem cell (ADSC). Muse cells can be prepared using "non-expression"
of markers unique to these cells as an index. More specifically, Muse cells
can
be isolated using as an index non-expression of at least one, e.g., 2, 3, 4,
5, 6, 7,
8,9, 10 or 11, of 11 markers selected from the group consisting of CD34 (a
marker for EP and ADSC), CD117 (c-kit) (a marker for MB), CD146 (a marker
for PC and ADSC), CD271 (NGFR) (a marker for NCSC), NG2 (a marker for
PC), vWF factor (von Willebrand factor) (a marker for EP), Sox10 (a marker for
NCSC), Snail (a marker for SKP), Slug (a marker for SKP), Tyrpl (a marker for
MB), and Dct (a marker for MB). Muse cells can be prepared by using as an
index non-expression of, for example, but not limited to, CD117 and CD146;
16
4 4
CA 03067963 2019-12-19
. =
. =
CD117, CD146, NG2, CD34, vWF and CD271; or the above-described 11
markers.
[0027]
The Muse cell having the above-described characteristics and used in the
cell product of the present invention also has at least one selected from the
group
consisting of the following characteristics:
(i) having low or no telomerase activity;
(ii) capable of differentiating into any of tridermic cells;
(iii) showing no neoplastic proliferation; and
(iv) having self-renewal capacities.
Preferably, the Muse cell to be used in the cell product of the present
invention
has all of the characteristics described above.
With respect to (i) above, the phrase "having low or no telomerase
activity" means that the telomerase activity is low or undetectable when
detected
using, for example, TRAPEZE XL telomerase detection kit (Millipore). Having
"low" telomerase activity means, for example, having a telomerase activity
comparable to somatic human fibroblast, or having 1/5 or less telomerase
activity, preferably 1/10 or less telomerase activity, as compared with that
of
HeLa cell.
With respect to (ii) above, the Muse cell is capable of differentiating into
triploblastic cells (endodermal, mesodermal, and ectodermal cells) in vitro
and in
vivo. For example, the Muse cell can be differentiated into hepatocyte
(including cells expressing hepatoblastoma or hepatocyte markers), neuron,
skeletal muscle cell, smooth muscle cell, osteocyte, or adipocyte by in vitro
inductive culturing. The Muse cell may also be capable of differentiating into
triploblastic cells when it is transplanted in testis in vivo. Further, the
Muse cell
17
= =
CA 03067963 2019-12-19
. .
is capable of migrating and engrafting to injured organs (such as heart, skin,
spinal cord, liver, and muscle) when transferred to a living body via
intravenous
injection and differentiating into cells corresponding to tissues.
With respect to (iii) above, the Muse cells are characterized by
proliferating at a growth rate of about 1.3 days and proliferating from one
cell in
suspension culture to form embryoid body-like cell aggregates and arrest their
proliferation after about 14 days when the aggregates reach a certain size.
When these embryoid body-like cell aggregates are transferred to adherent
culture, the cells restart proliferation and cells proliferated from the cell
aggregates spread at a growth rate of about 1.3 days. Further, the cells are
characterized in that, when transplanted into testis, they do not become
cancerous for at least half a year.
With respect to (iv) above, the Muse cell has self-renewal (self-
replication) capacities. The term "self-renewal" means that the followings can
be observed: differentiation into three-germ layer cells from cells contained
in
first embryoid body-like cell aggregates obtained by culturing one Muse cell
in a
suspension culture; as well as formation of second next-generation embryoid
body-like cell aggregates by again culturing one cell of the first embryoid
body-
like cell aggregates in a suspension culture; and further differentiation into
three-germ layer cells and formation of third embryoid body-like cell
aggregates
in a suspension culture from the second embryoid body-like cell aggregates.
Self-renewal may be repeated for one or more cycles.
[0028]
(2) Preparation and Use of Cell Product Comprising Muse Cell
The cell product comprising Muse cells of the present invention is
obtained by, but the method is not limited thereto, suspending the Muse cells
or
18
* =
CA 03067963 2019-12-19
. .
. =
the cell population containing the Muse cells obtained in (1) above in a
physiological saline or a suitable buffer solution (e.g., phosphate buffered
saline). In this case, if only small numbers of Muse cells are isolated from
an
autologous or allogeneic tissue, these cells may be cultured before cell
transplantation until the determined number of cells is attained. As
previously
reported (W02011/007900), since Muse cells do not become tumorigenic, even if
cells collected from a living tissue are contained while remaining
undifferentiated, they have low possibility of converting to malignant cells
and
thus are safe. The collected Muse cells can be cultured in any normal growth
medium (e.g., alpha-minimum essential medium (a-MEM) supplemented with
10% calf serum). More specifically, with reference to the above-described
W02011/007900, Muse cells can be cultured and proliferated using an
appropriately selected culture medium, additives (e.g., antibiotics, and
serum)
and the like, to prepare a solution containing Muse cells at the determined
concentration. When the cell product comprising Muse cells of the present
invention is administered to a human subject, bone marrow fluid can be
collected
from a human ilium. Then, for example, bone marrow mesenchymal stem cells
can be cultured as adherent cells obtained from the bone marrow fluid and
proliferated until they reach the cell amount where a therapeutically
effective
amount of Muse cells is obtained. Thereafter, Muse cells can be isolated using
an antigenic marker SSEA-3 as an index, and these autologous or allogeneic
Muse cells can be prepared into a cell product. Alternatively, for example,
bone
marrow mesenchymal stem cells obtained from the bone marrow fluid can be
cultured under external stress conditions to proliferate and enrich Muse cells
until they reach a therapeutically effective amount. Then, these autologous or
allogeneic Muse cells can be prepared into a cell product.
19
= =
CA 03067963 2019-12-19
. .
=
[0029]
When the Muse cells are used in the cell product, the cell product may
contain dimethyl sulfoxide (DMSO), serum albumin and the like for protection
of
the cells and antibiotics and the like for prevention of contamination and
proliferation of bacteria. The cell product may further contain other
pharmaceutically acceptable components (e.g., carrier, excipient,
disintegrant,
buffer agent, emulsifier, suspending agent, soothing agent, stabilizer,
preservative, antiseptic, physiological saline). These agents and drugs can be
added to the cell product at appropriate concentrations by the skilled person.
Thus, Muse cells can also be used as a pharmaceutical composition containing
various additives.
[0030]
The number of Muse cells contained in the cell product prepared above
can be appropriately adjusted to achieve desired effects in treatment of
epidermolysis bullosa, in consideration of, for example, sex, age, and weight
of
the subject, condition of the affected area, and condition of the cell to be
used.
Individuals as the subject includes, but not limited to, mammals such as
human.
The cell product comprising Muse cells of the present invention may be
administered multiple times at appropriate intervals (e.g., twice a day, once
a
day, twice a week, once a week, once every two weeks, once a month, once every
two months, once every three months, or once every six months) as appropriate
until a desired therapeutic effect is achieved. Thus, depending on the state
of the
subject, preferred therapeutically effective amount is, for example, ix 10 to
lx101 cells/individual/dose in 1 to 10 doses per year. Examples of total
dosage
for an individual include, but not limited to, 1x103 to 1x1011 cells,
preferably
lx 104 to lx 10" cells, more preferably lx 105 to 1 x109 cells.
=
CA 03067963 2019-12-19
[0031]
The Muse cell to be used in the cell product of the present invention is
characterized by migrating and engrafting to damaged skin from epidermolysis
bullosa. Thus, the cell product may be administered to any site by any method,
e.g., locally to the affected area or intravenously to a vein.
[0032]
The cell product comprising Muse cells of the present invention can
repair and regenerate a damaged skin of a patient with epidermolysis bullosa.
Repair and regeneration of the damaged skin can be determined by, for example,
recovery and/or increase of expression of collagen proteins such as COL7 and
COL17. Thus, the cell product comprising Muse cells of the present invention
has an effect of recovering and/or increasing expression of collagen proteins.
[0033]
<2> Skin Cell Differentiated from Muse Cell and Cell product Comprising the
Skin Cell
In the present invention, skin cells differentiated from Muse cells, such
as keratinocytes and/or fibroblasts, can be used as a cell product.
Keratinocytes refer to a cell that produces keratin and also referred to as
epidermal cell or keratinized cell. Muse cells can be differentiated into
keratinocytes, for example, by culturing Muse cells in a culture medium
containing keratinocyte growth factor (KGF) and epidermal growth factor (EGF),
preferably by culturing Muse cells in a culture medium containing KGF and EGF
followed by culturing in a culture medium containing KGF, EGF, hepatocyte
growth factor (HGF), and insulin-like growth factor 2 (IGF2). Preferred and
exemplified concentrations range from 5 to 20 ng/ml for KGF, from 20 to 40
ng/ml for EGF, and from 40 to 80 ng/ml for IGF2. Preferred and exemplified
21
k s
CA 03067963 2019-12-19
=
culturing period ranges from 7 to 28 days.
Fibroblasts refer to a cell that produces dermis components such as
collagen and elastin. Muse cells can be differentiated into fibroblasts, for
example, by culturing Muse cells in a culture medium containing transforming
growth factor-132 (TGF-132) and ascorbic acid (AA), preferably by culturing
Muse
cells in a culture medium containing TGF-132 and AA followed by culturing in a
culture medium containing AA. Preferred and exemplified concentrations range
from 30 to 60 g/m1 for TGF-132, and from 20 to 80 mmo1/1 for AA. Preferred
and exemplified culturing period ranges from 7 to 28 days.
[0034]
The cell product comprising skin cells differentiated from Muse cells,
such as keratinocytes and/or fibroblasts, can be used in treatment not only
for
epidermolysis bullosa but also for skin diseases in general that are curable
by
skin cell replacement therapy.
[0035]
When the cell product comprising skin cells differentiated from Muse
cells is used, the cell product may contain dimethyl sulfoxide (DMSO), serum
albumin and the like for protection of the cells and antibiotics and the like
for
prevention of contamination and proliferation of bacteria. The cell product
may
further contain other pharmaceutically acceptable components (e.g., carrier,
excipient, disintegrant, buffer agent, emulsifier, suspending agent, soothing
agent, stabilizer, preservative, antiseptic, physiological saline).
[0036]
The dose of the cell product can be appropriately adjusted to achieve
desired effects in treatment of a skin disease, in consideration of, for
example,
sex, age, and weight of the subject, condition of the affected area, and
condition
22
= =
CA 03067963 2019-12-19
of the cell to be used. Individuals as the subject includes, but not limited
to,
mammals such as human. The cell product may be administered multiple times
at appropriate intervals (e.g., twice a day, once a day, twice a week, once a
week,
once every two weeks, once a month, once every two months, once every three
months, or once every six months) as appropriate until a desired therapeutic
effect is achieved. Thus, depending on the state of the subject, preferred
therapeutically effective amount is, for example, lx 103 to lx 1010
cells/individual/dose in 1 to 10 doses per year. Examples of total dosage for
an
individual include, but not limited to, lx 103 to lx 1011 cells, preferably lx
10 to
lx101 cells, more preferably lx 105 to lx 109 cells. The cell product may be
administered by any method, and local administration to a site affected by a
skin
disease or its periphery is preferred. The skin cell may be formed into a
sheet
and applied to the affected site.
[0037]
The present invention will be described in more detail with reference to
examples below, but is not limited to the examples in any way.
EXAMPLES
[0038]
Preparation of Human Muse Cell
Muse cells were obtained according to the method described in
W02011/007900 on isolation and identification of human Muse cells. The Muse
cells were obtained by expansive enrichment culture of mesenchymal stem cells
under stress conditions. A commercially available MSC was purchased and used
as the MSC group.
[0039]
23
CA 03067963 2019-12-19
Example 1. Evaluation with Full-thickness Wound Model Mouse
A full-thickness wound was made on the back of an adult C57BL/6
mouse, and the mouse was used as a full-thickness wound model. Within 30
minutes after full-thickness wounding, the above-prepared Muse cells (3 x 105
per mouse or 3 x 104 per mouse), MSCs (3x105 per mouse), or 200 ill of HBSS
was injected into the tail vein, and then the therapeutic effect was
investigated.
The epithelization rate was calculated as below.
The back skins at the time of wounding and at day 3, 6, 9, and 11 after
wounding were photographed with a digital camera together with a ruler, and
then the skin ulcer areas (mm2) were determined using Image J software
(version
1.50i). Using the area at the time of wounding as a reference value, the
percent
area reduction was calculated.
Area at the time of wounding (mm ¨ Ulcer area at each day (mm 2)
Epithelization rate (%) = --------------------------------------- X 1 0 0
Area at the time of wounding (mm
[0040]
The results are shown in FIGS. 1 and 2. In all groups, the wounds were
healed with time. At day 3, the Muse cell (3 x 105 per mouse)-treated group
showed a significantly faster healing and higher epithelization rate than the
MSC-treated group and the HBSS-treated group, demonstrating that
administration of Muse cells is effective in treatment of epidermolysis
bullosa.
[0041]
At day 14, removing the skin tissue at the wound site, it was prepared
into a section and then stained for nucleus and human COL7. As shown in FIG.
3, it was found that the Muse cell-treated group showed the presence of human
COL7 in epidermis and dermis, demonstrating that the administered Muse cells
migrated to the skin and produced the molecule that is needed for adhesion
24
=
CA 03067963 2019-12-19
= =
between epidermis and dermis.
[0042]
Example 2. Evaluation with COL17-knockout Epidermolysis Bullosa Model
Mouse
Using a 3 to 4-week C0L17 gene-knockout mouse (see Nat Med. 2007
Mar; 13 (3): 378-83.), the epidermis was chafed to form a blister. Then,
within
30 minutes after the blister formation, Muse cells (3 x 105 per mouse) were
injected into the tail vein. Observing the skin state after one month, as
shown in
FIG. 4, the control mouse treated with HBSS had a poor hair coat, showing
extensive formation of wounds and mucosal erosion, while the mouse treated
with Muse cells gave mild results for both hair coat and wound formation. In
addition, the skin tissue one month after the administration was removed, and
RNA was extracted from the skin tissue. RT-PCR was performed to examine the
expression of human-derived COL7 and COL17 genes. The results are shown in
FIG. 5. As can be seen from the results, the Muse cell-administered mice
showed the presence of human COL7 and human C0L17, and thus the
administered Muse cells provided the adhesion factors. The expression of human
COL7 was also detected at protein level (FIG. 6).
[0043]
Example 3. Differentiation of Muse Cells into Keratinocytes
Differentiation of Muse cells into keratinocytes was made by culturing
them according to the following procedure:
Day 0: plating Muse cells;
Day 1: culturing them in a DMEM low glucose medium supplemented
with 10% FBS, KGF (10 ng/ml), and EGF (20 to 30 ng/ml) for three days; and
Day 4: culturing them in a DMEM low glucose medium supplemented
o .
CA 03067963 2019-12-19
,
with 10% FBS, KGF (10 ng/ml), EGF (20 to 30 ng/ml), HGF (10 ng/ml), and
IGF2 (60 ng/ml) for 8 to 14 days with the culture medium exchanged every other
day.
[0044]
The results are shown in FIGS. 7 to 9. As shown in FIG. 7, cells at day 8
of differentiation showed keratinocyte-like morphology. In addition, as shown
in
FIGS. 8 and 9, differentiated cells expressed keratinocyte markers at protein
and
mRNA levels.
[0045]
Example 4. Differentiation of Muse Cells into Fibroblasts
Differentiation of Muse cells into fibroblasts was made by culturing them
according to the following procedure:
Day 0: plating Muse cells;
Day 1: culturing them in 10 ml of DMEM low glucose medium
supplemented with 2 I of TGF-132 (50 g/ml), 60 I of AA (50 mM), and 100 I
of ITS-A (Insulin, Transferrin, Sodium selenite) for 6 days with the culture
medium exchanged every other day:
Day 7: culturing them in a DMEM low glucose medium supplemented
with 20% FBS and 60 I of AA (50 mM) for 10 days with the culture medium
exchanged every other day: and
Day 17: culturing them in a DMEM low glucose medium supplemented
with 10% FBS.
[0046]
The results are shown in FIGS. 10 to 12. As shown in FIG. 10, cells at
day 10 of differentiation showed fibroblast-like morphology. In addition, as
shown in FIGS. 11 and 12, differentiated cells expressed fibroblast markers at
26
=
CA 03067963 2019-12-19
=
protein and mRNA levels.
Industrial Applicability
[0047]
The cell product of the present invention can be administered to a patient
with epidermolysis bullosa to reconstruct and repair the damaged skin,
ameliorating or healing the skin symptoms, and thus can be applied to
treatment
of epidermolysis bullosa.
27
